Replies to post #11468 on CryoPort Inc (CYRX)

[stockwatchman101]

I hate to say this, but over the years I have seen that CYRX mgmt seems to usually get the votes they need to do anything they want in a pinch. Seems like a harsh reality to me...

[epcjmc]

Ask and ye shall receive . . .

Carrie Williams-November 16, 2018, 2:50 PM EDTSHARE ON:
Today, a Director at CryoPort Inc (CYRX), Richard J. Berman, bought shares of CYRX for $92.1K.

This is Berman’s first Buy trade following 5 Sell transactions.

Based on CryoPort Inc’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $5.29 million and GAAP net loss of $2.14 million. In comparison, last year the company earned revenue of $3 million and had a GAAP net loss of $1.98 million. Currently, CryoPort Inc has an average volume of 66.8K. The Company has a Price to Book ratio of 10.3634.

Starting in November 2017, CYRX received 11 Buy ratings in a row.

In the last 30 days, insiders have sold $301.6K worth of CYRX shares and purchased $92.1K worth of CYRX shares. The insider sentiment on CryoPort Inc has been negative according to 16 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Richard J. Berman’s trades have generated a -68.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Lake Forest, CA.